辉瑞：肥胖领域风险降低推动重估潜力-20260205

Investment Rating - The report maintains a "Buy" rating for Pfizer Inc. (PFE US) with a target price of $35.46, down from the previous target of $36.16, reflecting a potential upside of 32.4% from the current price of $26.78 [5][7]. Core Insights - Pfizer reported strong Q4 2025 results with revenues of $17.6 billion, aligning closely with the forecast of $18 billion. Adjusted net income was $3.8 billion, exceeding the estimate of $3.3 billion. Excluding COVID-19 products, operational revenue grew by 6% year-over-year, indicating a robust business foundation [3]. - The management reiterated revenue guidance for 2026 at $59.5 billion to $62.5 billion, with adjusted EPS projected between $2.80 and $3.00. Anticipated catalysts for 2026 include key data releases for long-acting GLP-1 and insulin projects, as well as positive clinical progress for obesity products and PF'4404 [3][5]. - The VESPER-3 study results for PF'3944 showed a 12.3% weight reduction at the medium dose, with expectations for the high dose to achieve a 15.8% reduction, positioning it competitively against alternatives [4]. - Pfizer is rapidly advancing the integration of PF'4404 (PD-1/VEGF) with its leading ADC product portfolio, aiming to establish a dominant position in the oncology market [5]. Financial Summary - For FY2026, revenue is projected at $60.7 billion, with a year-over-year decline of 2.9%. Adjusted net income is expected to be $16.34 billion, reflecting an 8.8% decrease from the previous year [6][16]. - The report outlines a decrease in P/E ratios, with FY2026 expected at 14.1x, down from 19.6x in FY2024, indicating a shift in valuation metrics [6][17]. - The DCF valuation estimates a share value of $35.46, based on a WACC of 9.95% and a terminal growth rate of 2.0% [13][14].